The global "pecking order" of blockbuster drugs has undergone a major shift, with seven out of 10 top-selling drugs now being biologics, reported The Times of India.
Analyst Sujay Shetty of PwC India said "the regulatory pathways [of biosimilars] are still challenging in the US, [but] in Europe there have been launches, and we will see more in coming years."
Shetty noted that "their sales have overtaken [that of] traditional drugs as these are high-value therapies aimed at chronic conditions such as oncology."
According to the news source, biologics have seen sales increase year on year, while chemically synthesised drugs have experienced plunging sales, with Gilead Sciences' Harvoni being the lone drug to have bettered sales over the last two years.
Meanwhile, in India, the biosimilar market across various players is valued at $300 million to $400 million.
The news source said several biosimilars by DRL, Intas, Biocon, Zydus and Emcure are in the local market with therapies addressing oncology, anti-inflammatory, anti-virals, rheumatoid arthritis and diabetes, while a small portion is exported.
To read more NewsPoints articles, click here.